MURATA-MANUFACTURING
24.3.2021 04:02:13 CET | Business Wire | Press release
In April, Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) will begin a service in Indonesia that will provide data from a traffic counter system mapping traffic volume via local service providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005470/en/
The system developed by Murata uses LiDAR technology*1 which has superior environmental adaptability compared to cameras, for its main sensor in order to adapt to changing analytical conditions, such as rain or darkness. With high-precision sensing, the system can reliably generate not only traffic volume data, but also traffic data that classifies vehicle-type information, such as passenger cars and large vehicles. This enables strategic advertising tailored to the desired time frame and vehicle-type data, for example, by displaying ads for specific products for B2B targets during commuting hours. By mapping regional traffic volumes, the system is also expected to see increased use as reference data for city planning, such as for the construction of shopping malls in locations with significant traffic levels.
The data provision service based on this system will start in Indonesia and later expand to the ASEAN region including Thailand and Malaysia.
The president of Murata Manufacturing, Norio Nakajima, issued the following statement.
“As a comprehensive electronic components maker, Murata Manufacturing since its founding has created products to support our customers who work in communications. As the digital transformation*2
continues globally, we are striving to not only provide electronic components and devices as before, but also to develop new digital business, including the provision of sensing data that will contribute to concrete solutions. We are working on boosting the digital information infrastructure in Southeast Asia with this new system and will contribute to the development of data visualization and digital transformation in countries around the world.”
Characteristics of the Traffic Counter System
- Uses LiDAR technology with high positioning performance as its sensor unit. Conducts stable measurements even under conditions such as rain and darkness, simultaneously capturing targets’ movement speed and volume, and classifying vehicles on the road.
- In addition to predicting rain based on CO2 and atmospheric pressure sensors, digitizes environmental data of the roads.
- Provides predictive rain data in pre-determined areas by analyzing environmental information.
- Customizable sensor functions responsive to client needs based on housing design that ensures extensibility.
- Creates a mesh network at a low cost.
- Can be implemented into existing infrastructure such as streetlights and pedestrian bridges.
- Provides analytical data via a dedicated cloud server.
- Gathers road traffic and environmental data captured with installed sensors provides real-time data and data processed via original algorithms, on a dedicated cloud server.
For details, please watch this video about the traffic counter system .
*1 Technology that measures the distance to a target by shining a laser on it and capturing the reflected laser light with an optical unit.
*2 The transformation of society and people’s lives for the better through the spread of information technology
Murata in Brief
Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. For more information, visit Murata's website at www.murata.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005470/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
